Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

CompletedOBSERVATIONAL
Enrollment

238

Participants

Timeline

Start Date

May 6, 2016

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
RAS Wild Type mCRC
Trial Locations (24)

10003

Research Site, Cáceres

12002

Research Site, Castellon

18014

Research Site, Granada

25198

Research Site, Lleida

28009

Research Site, Madrid

28034

Research Site, Madrid

28041

Research Site, Madrid

28046

Research Site, Madrid

30008

Research Site, Murcia

30202

Research Site, Cartagena

32005

Research Site, Ourense

33011

Research Site, Oviedo

33400

Research Site, Avilés

37007

Research Site, Salamanca

38320

Research Site, San Cristóbal de La Laguna

41013

Research Site, Seville

46014

Research Site, Valencia

46015

Research Site, Valencia

46026

Research Site, Valencia

04009

Research Site, Almería

07198

Research Site, Palma de Mallorca

09006

Research Site, Burgos

08221

Research Site, Terrassa

03010

Research Site, Alicante

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02792478 - Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study | Biotech Hunter | Biotech Hunter